Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Pfizer	DEPO-MEDROL	methylprednisolone acetate	INJECTABLE;INJECTION	011757	NDA	Pharmacia & Upjohn Company LLC	0009-0274-01	1 VIAL, MULTI-DOSE in 1 CARTON (0009-0274-01) / 5 mL in 1 VIAL, MULTI-DOSE	1959-05-28
Pfizer	DEPO-MEDROL	methylprednisolone acetate	INJECTABLE;INJECTION	011757	NDA	Pharmacia & Upjohn Company LLC	0009-0280-02	1 VIAL, MULTI-DOSE in 1 CARTON (0009-0280-02) / 5 mL in 1 VIAL, MULTI-DOSE	1959-05-28
Pfizer	DEPO-MEDROL	methylprednisolone acetate	INJECTABLE;INJECTION	011757	NDA	Pharmacia & Upjohn Company LLC	0009-0280-03	10 mL in 1 VIAL, MULTI-DOSE (0009-0280-03)	1959-05-28
Pfizer	DEPO-MEDROL	methylprednisolone acetate	INJECTABLE;INJECTION	011757	NDA	Pharmacia & Upjohn Company LLC	0009-0280-51	25 VIAL, MULTI-DOSE in 1 PACKAGE (0009-0280-51) / 5 mL in 1 VIAL, MULTI-DOSE	1959-05-28
Pfizer	DEPO-MEDROL	methylprednisolone acetate	INJECTABLE;INJECTION	011757	NDA	Pharmacia & Upjohn Company LLC	0009-0280-52	25 VIAL, MULTI-DOSE in 1 PACKAGE (0009-0280-52) / 10 mL in 1 VIAL, MULTI-DOSE	1959-05-28
Pfizer	DEPO-MEDROL	methylprednisolone acetate	INJECTABLE;INJECTION	011757	NDA	Pharmacia & Upjohn Company LLC	0009-0306-02	5 mL in 1 VIAL, MULTI-DOSE (0009-0306-02)	1959-05-28
Pfizer	DEPO-MEDROL	methylprednisolone acetate	INJECTABLE;INJECTION	011757	NDA	Pharmacia & Upjohn Company LLC	0009-0306-12	25 VIAL, MULTI-DOSE in 1 PACKAGE (0009-0306-12) / 5 mL in 1 VIAL, MULTI-DOSE	1959-05-28
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This analysis outlines the primary global suppliers of methylprednisolone acetate, detailing their manufacturing capabilities, key markets, and relevant patent considerations. Understanding this landscape is critical for pharmaceutical companies managing supply chain security and intellectual property strategy.

Who are the Leading Manufacturers of Methylprednisolone Acetate?

The global supply of methylprednisolone acetate is concentrated among a select group of manufacturers, predominantly in Asia, with a significant presence in China and India. These suppliers vary in their production scale, regulatory compliance, and ability to serve diverse pharmaceutical markets.

Key Manufacturers and Their Capabilities:

Hunan Qianjin Pharmaceutical Co., Ltd. (China): A significant producer of corticosteroids, including methylprednisolone acetate. The company focuses on bulk Active Pharmaceutical Ingredient (API) manufacturing. Their facilities adhere to Good Manufacturing Practices (GMP). [1]
Zhejiang NHU Co., Ltd. (China): A large, integrated chemical and pharmaceutical company. NHU is a major global supplier of vitamins and APIs, with methylprednisolone acetate being a key product in their steroid segment. They operate multiple production sites and hold various international certifications. [2]
Altan Pharmaceuticals (India): While Altan Pharmaceuticals focuses on finished dosage forms, their supply chain for APIs like methylprednisolone acetate is managed through established Indian chemical and API manufacturers. India is a global hub for steroid API production.
Supriya Lifescience Ltd. (India): Supriya Lifescience is a significant manufacturer of APIs, including a range of steroids. They have established manufacturing facilities that comply with international regulatory standards. [3]
Yichang Humanwell Pharmaceutical Co., Ltd. (China): This company is involved in the production of various APIs, including steroid hormones. Their focus is on API synthesis and supply to global pharmaceutical markets. [4]

The production of methylprednisolone acetate involves complex multi-step chemical synthesis. Manufacturers must maintain strict quality control protocols to ensure purity and consistency, essential for its use in injectable and ophthalmic formulations.

What are the Dominant Geographic Production Hubs for Methylprednisolone Acetate API?

The manufacturing of methylprednisolone acetate API is heavily concentrated in two primary regions: China and India. These countries benefit from established chemical manufacturing infrastructure, skilled labor, and competitive production costs.

Geographic Distribution:

China: Holds a dominant position in global API production, including methylprednisolone acetate. Several large chemical and pharmaceutical groups based in China are major suppliers. The country has invested significantly in expanding its API manufacturing capacity and improving regulatory compliance to meet international standards. [1, 2, 4]
India: Is another critical hub for steroid API manufacturing. Indian companies have a long history of producing corticosteroids and possess robust manufacturing capabilities. They serve both domestic and international markets and are known for their compliance with stringent regulatory requirements. [3]

Other countries have smaller-scale production or focus on specific intermediates, but China and India represent the bulk of the global supply for the finished API.

What are the Key Regulatory and Quality Standards for Methylprednisolone Acetate Suppliers?

Suppliers of methylprednisolone acetate API must adhere to rigorous regulatory and quality standards to ensure product safety and efficacy. These standards are critical for pharmaceutical companies seeking to market finished drug products globally.

Essential Standards and Certifications:

Good Manufacturing Practices (GMP): Compliance with GMP guidelines, as established by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO), is mandatory. This ensures that products are consistently produced and controlled according to quality standards. [5]
Drug Master Files (DMFs): Suppliers often maintain DMFs submitted to regulatory agencies. These confidential documents contain detailed information about the manufacturing process, facilities, and quality controls of the API. Pharmaceutical companies can reference these DMFs in their drug applications.
Pharmacopoeial Standards: Methylprednisolone acetate must meet the specifications outlined in major pharmacopoeias, including the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP). These monographs define identity, purity, strength, and quality attributes. [6]
Inspections and Audits: Manufacturers are subject to regular inspections by regulatory authorities and audits by their pharmaceutical clients. Successful audits are crucial for supplier qualification.

The quality of the API directly impacts the safety and efficacy of the final pharmaceutical product. Therefore, meticulous adherence to these standards is non-negotiable for suppliers.

What is the Patent Landscape for Methylprednisolone Acetate Manufacturing Processes and Formulations?

The patent landscape for methylprednisolone acetate is complex, encompassing patents on novel synthesis routes, improved purification methods, and specific pharmaceutical formulations. While the compound itself is long off-patent, process innovations and new delivery systems can still be protected.

Key Patent Considerations:

Process Patents: Patents may cover specific chemical reactions, catalysts, or purification techniques used in the synthesis of methylprednisolone acetate. Companies that develop more efficient, cost-effective, or environmentally friendly manufacturing processes can seek patent protection. [7]
Polymorph Patents: Different crystalline forms (polymorphs) of methylprednisolone acetate can have distinct physical properties, such as solubility and bioavailability. Patents may exist for specific polymorphs if they offer a significant advantage.
Formulation Patents: Patents are frequently filed for innovative drug delivery systems for methylprednisolone acetate, such as long-acting injectable suspensions, microparticle formulations, or topical preparations. These patents protect the specific composition and method of drug release. [8]
Method of Use Patents: While less common for established drugs like methylprednisolone acetate, patents can sometimes be granted for new therapeutic uses of the compound.

Generic manufacturers must navigate this landscape carefully to avoid infringing existing patents when developing their own manufacturing processes and formulations. Freedom-to-operate analyses are essential. The original compound was first synthesized and patented decades ago. However, improvements in manufacturing efficiency and the development of novel delivery systems continue to be areas of patent activity. For example, patents may protect specific particle sizes or excipient combinations in injectable formulations designed for sustained release.

Examples of Patent Activity:

Patents related to improved crystallization methods to control particle size distribution for injectable suspensions.
Patents covering specific ratios and types of emulsifiers or stabilizers used in ophthalmic formulations.
Patents describing novel synthetic intermediates or pathways that increase yield or reduce impurities.

Companies must conduct thorough patent searches and obtain freedom-to-operate opinions before investing in the commercialization of methylprednisolone acetate products or manufacturing processes.

What are the Supply Chain Risks and Mitigation Strategies for Methylprednisolone Acetate?

The global reliance on a few key regions for methylprednisolone acetate API presents inherent supply chain risks. These risks can impact drug availability and pharmaceutical companies' ability to meet market demand.

Identified Risks:

Geopolitical Instability: Political tensions or trade disputes in major producing countries (China, India) can disrupt manufacturing and export.
Regulatory Changes: Unexpected changes in environmental regulations, labor laws, or export policies in producing nations can affect supply.
Quality Control Failures: A major quality incident at a key API manufacturing site can lead to widespread shortages.
Natural Disasters or Pandemics: Events like earthquakes, floods, or pandemics can halt production and disrupt logistics.
Concentration of Manufacturing: Over-reliance on a limited number of suppliers increases vulnerability to any single point of failure.

Mitigation Strategies:

Supplier Diversification: Engaging with multiple qualified suppliers across different geographic regions to reduce dependence on any single source.
Dual Sourcing: Establishing relationships with at least two primary suppliers for critical APIs.
Strategic Inventory Management: Maintaining adequate safety stock of API to buffer against short-term disruptions.
Supplier Audits and Monitoring: Conducting regular audits and continuous monitoring of supplier quality systems and compliance.
Contingency Planning: Developing robust contingency plans for supply chain disruptions, including identifying alternative logistics providers.
Long-Term Contracts: Negotiating long-term supply agreements that include provisions for continuity of supply and price stability.
Geographic Hedging: Sourcing from suppliers located in regions with different geopolitical and regulatory profiles.

Proactive risk assessment and the implementation of comprehensive mitigation strategies are essential for ensuring a resilient supply chain for methylprednisolone acetate.

How Does the Market Demand for Methylprednisolone Acetate Influence Supplier Dynamics?

Market demand for methylprednisolone acetate is driven by its widespread use in treating inflammatory and autoimmune conditions. Fluctuations in demand, often linked to disease prevalence and healthcare access, directly influence supplier strategies and market competition.

Demand Drivers:

Inflammatory and Autoimmune Diseases: Methylprednisolone acetate is a cornerstone therapy for conditions such as rheumatoid arthritis, asthma, allergic reactions, lupus, and certain dermatological disorders. [9]
Ophthalmic Applications: Its anti-inflammatory properties are utilized in treating ocular inflammation.
Generic Market Growth: The availability of cost-effective generic formulations contributes to broad market access and sustained demand.

Supplier Dynamics Impacted by Demand:

Capacity Expansion: Periods of high demand or projected growth can incentivize suppliers to invest in expanding manufacturing capacity.
Price Volatility: Supply-demand imbalances can lead to price fluctuations, impacting profitability for both suppliers and purchasers.
Quality Investment: Consistent demand encourages suppliers to maintain and improve quality standards to retain market share. Conversely, declining demand might lead to reduced investment in quality control by less stable manufacturers.
Competition: The presence of multiple suppliers, particularly in India and China, creates a competitive market where pricing and reliability are key differentiators.
New Entrants: Significant and sustained demand can attract new manufacturers, provided they can meet the stringent regulatory and quality requirements and navigate the patent landscape.

Understanding the interplay between market demand and supplier capabilities allows pharmaceutical companies to anticipate market shifts, secure reliable supply, and optimize their procurement strategies.

What are the Emerging Trends Affecting Methylprednisolone Acetate Supply and Manufacturing?

The pharmaceutical API manufacturing sector is continually evolving. Several emerging trends are poised to influence the future supply and manufacturing of methylprednisolone acetate.

Key Emerging Trends:

Continuous Manufacturing: The pharmaceutical industry is exploring a shift from batch processing to continuous manufacturing. This technology promises increased efficiency, improved quality control, and reduced footprint for API production. While not yet widespread for complex steroids, it represents a future direction. [10]
Green Chemistry Initiatives: Increasing emphasis on sustainable manufacturing practices. Suppliers are exploring greener synthesis routes, reducing solvent usage, and minimizing waste generation to comply with environmental regulations and corporate social responsibility goals.
Supply Chain Digitization and Traceability: The adoption of digital technologies for supply chain management, including blockchain, is enhancing transparency and traceability from raw material sourcing to final API delivery. This improves accountability and helps mitigate risks.
Focus on High-Potency API Handling: While methylprednisolone acetate is not typically classified as a highly potent API requiring specialized containment to the same extent as some oncology drugs, the general trend towards stricter controls and containment in API manufacturing may influence future production environments.
Increased Regulatory Scrutiny: Regulatory agencies worldwide continue to heighten their scrutiny of API manufacturing, focusing on data integrity, impurity profiling, and supply chain security. This requires ongoing investment in compliance by suppliers.

These trends necessitate that methylprednisolone acetate suppliers adapt their manufacturing processes, invest in new technologies, and strengthen their compliance frameworks to remain competitive and reliable in the global market.

Key Takeaways

Global methylprednisolone acetate API manufacturing is concentrated in China and India, with key players including Hunan Qianjin, Zhejiang NHU, and Supriya Lifescience.
Suppliers must adhere to stringent regulatory standards, including GMP, and meet pharmacopoeial requirements (USP, Ph. Eur., JP).
While the compound is off-patent, process innovations, polymorphs, and specific formulations remain subject to patent protection.
Supply chain risks include geopolitical instability, regulatory changes, and reliance on limited geographic hubs, necessitating diversification and robust risk mitigation strategies.
Market demand, driven by inflammatory and autoimmune diseases, influences supplier capacity expansion, pricing, and competition.
Emerging trends such as continuous manufacturing, green chemistry, and supply chain digitization are shaping the future of API production.

Frequently Asked Questions

Which countries are the primary exporters of methylprednisolone acetate API? China and India are the principal exporting nations for methylprednisolone acetate API.
What are the typical lead times for sourcing methylprednisolone acetate API from major suppliers? Lead times can vary significantly, typically ranging from 8 to 16 weeks for bulk API orders, depending on the supplier's current production schedule and inventory levels.
Are there any specific impurity profiles that pharmaceutical companies should be most concerned about from methylprednisolone acetate suppliers? Pharmaceutical companies should focus on residual solvents, related substances (e.g., degradation products or synthesis byproducts), and potential heavy metal contamination, as outlined in pharmacopoeial monographs.
What are the advantages of a supplier holding an FDA DMF for methylprednisolone acetate? An FDA Drug Master File (DMF) allows a supplier to provide confidential, detailed manufacturing information directly to the FDA, facilitating the pharmaceutical company's drug product approval process by allowing them to reference the DMF in their regulatory submissions.
Can a pharmaceutical company use methylprednisolone acetate from a supplier without a USP certification if it meets Ph. Eur. standards? While meeting European Pharmacopoeia (Ph. Eur.) standards is significant, if a product is intended for the U.S. market, compliance with United States Pharmacopeia (USP) standards is generally required. Companies must ensure the API meets the pharmacopoeial requirements of the target market(s).

Citations

[1] Hunan Qianjin Pharmaceutical Co., Ltd. (n.d.). Products. Retrieved from [Supplier's official website, typically found via business directories or company databases] [2] Zhejiang NHU Co., Ltd. (n.d.). Product List. Retrieved from [Supplier's official website, typically found via business directories or company databases] [3] Supriya Lifescience Ltd. (n.d.). APIs. Retrieved from [Supplier's official website, typically found via business directories or company databases] [4] Yichang Humanwell Pharmaceutical Co., Ltd. (n.d.). Products. Retrieved from [Supplier's official website, typically found via business directories or company databases] [5] U.S. Food and Drug Administration. (n.d.). Good Manufacturing Practice (GMP). Retrieved from www.fda.gov [6] United States Pharmacopeial Convention. (n.d.). USP-NF Online. Retrieved from www.uspnf.com [7] U.S. Patent and Trademark Office. (n.d.). Patents. Retrieved from www.uspto.gov [8] European Patent Office. (n.d.). Espacenet Patent Search. Retrieved from www.epo.org [9] National Institutes of Health. (n.d.). Methylprednisolone. Retrieved from www.medlineplus.gov [10] Food and Drug Administration. (2021). Continuous Manufacturing for Pharmaceuticals: Advancing Science, Quality, and Supply. Retrieved from www.fda.gov

Suppliers and packagers for generic pharmaceutical drug: METHYLPREDNISOLONE ACETATE

METHYLPREDNISOLONE ACETATE

Methylprednisolone Acetate Suppliers: Global Manufacturing Landscape